GSK Malaria Vaccine Gets Landmark Clearance For Use In Africa
WHO Recommendation Takes Account Of 2015 EMA Scientific Opinion
Mosquirix is set for much wider availability in sub-Saharan Africa thanks to positive results from a pilot program in Ghana, Kenya and Malawi. The next step is deciding how to fund the vaccine’s rollout over the coming years.
You may also be interested in...
The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency has recommended for approval the world's first vaccine for malaria1,2.
Chaos wrought by the ongoing coronavirus pandemic. A heavy workload and continuing resource constraints at the European Medicines Agency. Nonetheless, a record number of novel drugs and vaccines were cleared for marketing in the EU last year.
Challenges to the use of real-world data and the importance of wider international regulatory collaborations were among topics addressed by the European industry body EFPIA in a survey of its member companies.